🇺🇸 FDA
Patent

US 11407822

Treatment of fibrodysplasia ossificans progressiva

granted A61KA61K2039/505A61K38/179

Quick answer

US patent 11407822 (Treatment of fibrodysplasia ossificans progressiva) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K38/179, A61K39/39533, A61K39/3955